


PHARMACEUTICAL 2021

💢 BeiGene

BeiGene Ltd. Rank 160 of 409



PHARMACEUTICAL 2021

M BeiGene

BeiGene Ltd. Rank 160 of 409

The relative strengths and weaknesses of BeiGene Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BeiGene Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 90% points. The greatest weakness of BeiGene Ltd. is the variable Research and Development, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is -60%, being 295% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	4,960,690
Cost of Goods Sold	70,657
Intangible Assets	5,000
Liabilities, Current	1,075,199
Liabilities, Non-Current	656,315
Other Assets	277,381
Other Compr. Net Income	18,560
Other Expenses	-16,825
Other Liabilities	0
Other Net Income	39,488
Property and Equipment	357,686
Research and Development	1,294,877
Revenues	308,874
Selling, General and Administrative Expense	600,176

Output Variable	Value in 1000 USD
Assets	5,600,757
Liabilities	1,731,514
Expenses	1,948,885
Stockholders Equity	3,869,243
Net Income	-1,600,523
Comprehensive Net Income	-1,591,243
Economic Capital Ratio	-60%